

Comparative study between conventional crystalloid cardioplegic solution with modified del nido cardioplegia in mitral valve regurgitation surgery

Comparación entre cardioplejia convencional con cristaloides versus cardioplejia modificada del Nido en cirugía valvular mitral

Tarek Abdelsalam Seleem MD.¹, Mohamed Abdelgawad Abdelhalim Aboelsuod MD.¹, Mohamed Hussienny Mahmoud MD.², Mostafa Shaaban Abdelazeem¹

Department of Anesthesia, intensive care and pain management, Faculty of Medicine, Al-Azhar University. Cairo, Egypt.

Department of cardiothoracic surgery, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.

Funding: Nil. Conflict of interests: Non.

Reception: 27 de abril de 2023 / Acceptance: 05 de mayo de 2023

ABSTRACT

Background: Cardioplegia is crucial for protecting the heart. Long-term cardiac protection is offered by the Del Nido Cardioplegia solution (dNCS). Aim: To compare conventional crystalloid cardioplegia with modified del Nido cardioplegia in mitral valve regurgitation replacement surgery. Objectives and Methods: This randomized clinical study included 80 patients undergoing to elective mitral regurgitation replacement surgery of both sex and age from 21 to 60 years with ASA (III and IV). All 80 patients were randomly assigned to receive conventional cardioplegia (St. Thomas' cardioplegic solutions) or to obtain a modified del Nido cardioplegia (using normal saline) (groups A and B, respectively). The laboratory data for assessment of myocardial protection were obtained through measurements of preoperative serum levels of cardiac enzymes as, CK-MB, troponin, and lactate, immediately after operation, 12 and 24 hours postoperatively. Results: There was a significant increase in CK-MB only after 1 h (p < .001) in group (A) and after 12 h. CK-MB and lactate levels were significantly increased (p < 0.05). Also, after 24 h. CK-MB and Troponin T levels were significantly increased (p < .001). Regarding complications, one patient had atrial fibrillation and one case had permanent stroke in group (A), and two patients died in group (A), while one patient died in group (B) without a significant difference between the groups. Conclusions: We report that Modified Del Nido Cardioplegia has better postoperative chemical parameters as CK-MB, Troponin T and Lactate in mitral valve surgery in adults. DNC is a safe alternative to conventional cardioplegia and has achieved at least the same results.

Key words: Mitral valve regurgitation, crystalloid cardioplegia, modified del nido cardioplegia.

RESUMEN

Introducción: La cardioplejía es crucial para proteger el corazón. La solución Del Nido Cardioplegia (dNCS) podría ofrecer mejor protección cardíaca a largo plazo. Objetivo: Comparar la cardioplejía cristaloide convencional con la cardioplejía del Nido modificada en la cirugía de recambio valvular mitral. Objetivos y Métodos: Este estudio clínico aleatorizado incluyó a 80 pacientes sometidos a cirugía de recambio valvular mitral electiva de ambos sexos y edades de 21 a 60 años con ASA (III y IV). Los 80 pacientes fueron asignados al azar para recibir cardiopleiía convencional (soluciones cardiopléjicas de St. Thomas) o cardioplejía del Nido modificada (usando solución salina normal) (grupos A y B, respectivamente). Los datos de laboratorio para la evaluación de la protección miocárdica se obtuvieron a través de la medición de los niveles séricos preoperatorios de enzimas cardíacas como CK-MB, troponina y lactato, inmediatamente después de la operación y 12 y 24 h después de la operación. Resultados: Hubo un aumento significativo de CK-MB solo después de 1 h (p < 0,001) en el grupo (A) y después de 12 h. Los niveles de CK-MB y lactato aumentaron significativamente (p < 0,05). Además, pasadas las 24 h. Los niveles de CK-MB y troponina T aumentaron significativamente (p < 0,001). En cuanto a las complicaciones, un paciente presentó fibrilación auricular y un caso ictus permanente en el grupo (A), y dos pacientes fallecieron en el grupo (A), mientras que un paciente falleció en el grupo (B) sin diferencia significativa entre los grupos. Conclusiones: Reportamos que la Cardioplejía Del Nido Modificada tiene mejores parámetros químicos postoperatorios como CK-MB, Troponina T y Lactato en cirugía de válvula mitral en adultos. DNC es una alternativa segura a la cardioplejía convencional y ha logrado al menos los mismos resultados.

Palabras clave: Insuficiencia valvular mitral, cardioplejía cristaloide, cardioplejía modificada de del Nido.

moustafaomara2000@gmail.com *ORCID: https://orcid.org/0009-0009-4103-1560 ISSN: 0716-4076



Introduction

ardioplegia is essential for successful surgical outcomes because it protects the heart, slows metabolic activity, and increases the resistance of the myocardium to ischemia over extended periods of time[2].

The timing of cardioplegia administration is highly important to prevent myocardial dysfunction. A conventional multidose cardioplegia should be given every 15 to 20 min. Time is essential in open-heart surgery, and any disruption to the flow of the procedure, even if only for a few seconds, before each cardioplegia supply wastes precious minutes[3].

Finding a treatment that would permit longer re-dosing intervals, a longer time during which the heart could be safely ischemic, and similar myocardial protection would therefore be the best solution[4].

The inhibition of fast-acting sodium channels or calciumactivated processes is the mechanism by which crystalloid cardioplegic solutions induce cardiopulmonary arrest. Use for hyperkalemia in the St. Thomas Hospital solution and variants, blocking fast-acting sodium channels[5].

Crystalloid cardioplegia, such as St. Thomas' cardioplegic solution No. 2 (traditional cardioplegia), has been widely used by cardiac surgeons; nevertheless, it must be injected multiple times at frequent intervals. It has been observed that the postoperative prognosis is negatively affected by increases in myocardial acidity between doses. Therefore, it would be preferable if the time between cardioplegic doses could be lengthened, thereby decreasing the total number of doses administered[6].

Since the early 1990s, juvenile cardiac doctors have made effective use of del Nido cardioplegia solution (dNCS) due to its ability to provide long-term cardiac protection with a single dose [7]. The goal of our research was to match the effectiveness of modified del Nido cardioplegia to traditional crystalloid cardioplegia during mitral valve replacement surgery.

Material & Methods

In this potential Randomized, clinical trial research, include 80 cases scheduled for elective mitral regurgitation replacement surgery with normal coronaries of both sex and age from 21 to 60 years with ASA III and IV classification, were selected from attendee of cardiothoracic surgery clinics of Al-Azhar Hospitals during August 2022 to April 2023.

The total number was randomized by simple randomization into two groups: group (A) had 40 cases who received conventional cardioplegia (St. Thomas' cardioplegic solutions) and group (B) contained 40 patients who received normal salinebased modified del Nido cardioplegia.

Inclusion criteria

- Age: 21 50 years.
- Patients scheduled for elective mitral regurgitation replacement with normal coronaries.

Exclusion criteria

- Patients with renal disease.
- Left ventricular ejection fraction less than 50%.
- Previous cardiac surgery.

- Patient with BMI > 30.
- Severe psychiatric diseases.
- Inability to give informed consent for participation.

Methods

All patients had been subjected to complete history taking and complete physical examination. Each patient had been received the previously prepared cardioplegia according to his group.

Saline based del Nido formulation had been prepared as Nakao et al.[8], formula, and St. Thomas' formulation had been prepared as Mishra et al.[9] formula. Depending on the individual reason, the cardioplegic solutions were given anterogradely at the coronary ostia or root of the aorta. Just prior to their administration, the St. Thomas' Cardioplegia and Normal Saline Based Modified del Nido were altered at the time of service.

Typically, the solutions had been delivered at a temperature of 4° C, with a system pressure of 100-200 mmHg & an taking flow of 200-300 mL/min, with an extreme dose of 1,000 mL for cases weighing over 50 kg. Further dosages were administered every 20 minutes for St. Thomas (traditional cardioplegia), and after 90 minutes for modified del Nido if necessary.

Outcomes study:

Primary outcome: Assess myocardial protection through measurements of the serum levels of cardiac enzymes as CK-MB, troponin, and Lactate preoperative, just after the operation, 12 and 24 hours post-operative.

Secondary outcomes: Assessments of additional myocardial protection measures were done using ICON (noninvasive hemodynamics electrical cardiometry) which are Ejection Fraction (EF), Stroke volume (SV), the incidence of Stroke volume variation (SVV), Cardiac output (COP) and Cardiac index (CI). All every 2 hrs in first 6 hrs then every 6 hrs in first 24 h postoperative.

Sample size

This study base on the research carried out by Mishra et al.[9] Epi-Info STATCALC was used to sample size calculated by considering the following assumptions: - 95% two-sided confidence level, with a power of 80% & a error of 5% odds ratio calculated = 1,115. The final maximum sample size taken from the Epi-Info output was 72. Thus, the sample size was increased to 80 subjects to assume any drop out cases during follow up (Figure 1).

Ethical approval

Each patient had given their informed consent and the study had been approved by Institutional Review Board (IRB) (No.00255/2022) with accepted at clinical trial.org (NCT05797090).

Statistical analysis:

The information was entered into Statistical Program for the Social Sciences for codification, processing, and analysis (SPSS2) 1st edition, IBM, United States. Descriptive statistics were calculated. We compare between both groups by Chi-square test for categorical variables, Student T-test for normally distributed



Figure 1. Study flow chart.

quantitative variables, Mann Whitney test for abnormally distributed quantitative variables and friedman's test (Fr test) for continuous data to test for significant difference between more than two dependent non- parametric data along different time points.

Results

Eighty participants were split evenly between two groups for this investigation. There were 55% male & 45% women in group (A), with a median age of 49.75 ± 7.11 years; in group (B), the median age was 48.72 ± 8.51 years. Age, sex, ASA classification, body mass index, functional class according to the New York Heart Association, mitral regurgitation grade, cardiovascular comorbidity, and non-cardiac comorbidities did not differ significantly among the two groups (Table 1).

There was no significant difference between groups (A) and (B) in ejection fraction measured preoperatively and after 2 h postoperative. Meanwhile, there was a significant increase in

ejection fraction in group (B) matched to group (A) after 4, 6, 12, 18 and 24 h postoperative (p = 0.017, 0.001, < 0.001, < 0.001, respectively).

Preoperative, 2, 4, and 6-hour measures of stroke volume found no significant differences among groups (A) & (B). Meanwhile there was significant increase of stroke volume in group (A) matched to group (B) after 12, 18 and 24 h postoperative (p = 0.023, < 0.001 and < 0.001, respectively). Also, no significant difference was showed among group (A) & group (B) regarding cardiac output measured preoperative, after 2, 4, 6, 12, 18 and 24 h postoperative.

Postoperative inotropic support was used in 50% cases in group (A) & 40% cases in group (B). The mean number of inotropes was 1.43 ± 0.6 in group A & 1.39 ± 0.5 in group B. No significant difference was showed among the 2 groups according to postoperative inotropic support or number of inotropes (Table 2).

One unit of total PRBC Transfusion was needed for 40% case in group (A) & 15\% cases in group (B) while two units was

Table 1. Comparison of demographic and clinical data between groups								
Variables	ables		Group (A) (n = 40)	G	Group (B) (n = 40)			
		n	%	n	%			
Age (year)	Mean± SD	4	9.75± 7.11	48	3.72± 8.51			
	Median		50.0		49.5			
	Range	30.0 - 61.0)	32.0 - 67.0				
Sex	Male	22	55.0%	24	60.0%	0.651		
	Female	18	45.0%	16	40.0%			
ASA classification	III	28	70%	24	60%	0.428		
	IV	12	30%	16	40%			
BMI (Kg/m ²)	Mean ± SD	2	6.93± 1.65	26	5.98± 1.79			
	Median		27.0		27.0	0.815		
	Range	2	24.0 - 31.0		4.0 - 30.0			
NYHA functional	I	18	45.0%	21	52.5%			
class	Ш	12	30.0%	9	22.5%	0.657		
	III	8	20.0%	6	15.0%	0.057		
	IV	2	5.0%	4	10.0%			
Mitral regurgitation rade	Grade I	2	5.0%	1	2.5%			
	Grade II	11	27.5%	10	25.0%			
	Grade III	9	22.5%	7	17.5%	0.487		
	Grade IV	16	40.0%	15	37.5%			
	with MS	2	5.0%	7	17.5%			
Cardiovascular comorbidity	No	21	52.5%	26	65.0%			
	AF or flutter	1	2.5%	0	0.0%	0 551		
	HTN	16	40.0%	12	30.0%	0.551		
	PAD	2	5.0%	2	5.0%			
Non-cardiac	No	29	72.5%	29	72.5%	1.00		
comorbidity	DM	11	27.5%	11	27.5%			

BMI: Body mass index; ASA: American Society of Anesthesiologists; NYHA: New York Heart Association; AF: Atrial fibrillation; HTN: Hypertension, PAD: Peripheral Arterial Disease; DM: Diabetes mellitus.

Table 2. Comparison of postoperative inotropic support between the studied groups								
Variable		Grou (n =	p (A) : 40)	Gro (n	P-value			
		n	%	n	%			
Postoperative inotropic support	No	20	50.0%	24	60.0%	0.369		
	Yes	20	50.0%	16	40.0%			
Number of inotropes	Mean ± SD	1.43 ± 0.60		1.39 ± 0.50				
						0.723		
	Median	1.0	1.0					
	Range	0.0- 2.0	1.0- 2.0					

needed for 7.5% cases in group (A) only. Total PRBC Transfusion was significantly higher in group A matched to group B (Table 3).

0.001 for all). There was significant increase of Troponin T in group (A) matched to group (B) after 24 h only (p < 0.001). Also, there was significant rise of Lactate in group (A) compared to group (B) after 12 h only (p = 0.029) (Table 4).

There was significant increase of CK-MB in group (A) compared to group (B) after 1, 12 and 24 h postoperative (p <

The mean ventilation duration was 6.92 ± 0.62 h in group A

Table 3. Comparison of postoperative Total PRBC Transfusion between groups									
Variable		Group (A) (n = 40)		Gro (n	P-value				
		n	%	n	%				
Total PRBC Transfusion (units)	n	21	52.5%	34	85.0%				
	1 unit	16	40.0%	6	15.0%	0.005			
	2 units	3	7.5%	0	0.0%				
	Mean ± SD	0.55 ± 0.64		0.15 ± 0.36		0.001			
	Median	0.0	0.0						
	Range	0.0 - 2.0		0.0 - 1.0					

PRBC: Packed red blood cells.

Table 4.	Comparison be	etween the	e studied g	roups rega	rding CK-MB, Tro	ponin T a	nd Lactate	at differe	nt follow-u	o periods
	Group (A) (n = 40)				Group (B) (n = 40)				Test value	P-value
	Mean ± SD	Median	Min.	Max.	Mean \pm SD	Median	Min.	Max.		
CK-MB (ng/	mL)									
After first h	7.65 ± 0.97	7.6	5.9	9.2	5.75 ± 0.38	5.8	4.8	6.3	7.483	< 0.001
After 12 h	11.84 ± 0.68	11.8	10.9	13.7	9.66 ± 0.67	9.6	8.6	10.9	7.498	< 0.001
After 24 h	17.49 ± 0.95	17.8	15.7	18.8	13.03 ± 0.94	12.8	10.9	14.7	7.661	< 0.001
p-value•	< 0.001									
Troponin T	ˈ(ng/mL)									
After first h	0.21 ± 0.05	0.21	0.12	0.36	0.22 ± 0.04	0.22	0.15	0.34	0.156	0.876
After 12 h	0.34 ± 0.05	0.33	0.24	0.45	0.33 ± 0.06	0.30	0.28	0.54	1.734	0.083
After 24 h	0.63 ± 0.07	0.62	0.45	0.78	0.45 ± 0.14	0.43	0.23	0.78	5.481	< 0.001
p-value•	< 0.001				< 0.001					
Lactate (ng/mL)										
After first h	2.86 ± 1.03	3.0	1.0	5.0	2.90 ± 1.19	3.0	1.0	5.0	010-	0.992
After 12 h	6.58 ± 1.71	6.0	4.0	10.0	8.90 ± 10.03	7.5	5.0	70.0	-2.184-	0.029
	Group (A) (n = 40)				Group (B) (n = 40)					
After 24 h	4.00 ± 2.20	4.0	2.0	12.0	4.08 ± 2.52	3.5	1.0	15.0	030-	0.976
p-value•		< 0.0	01			< 0.00	1			

*p value between different periods in same group; CK-MB: Creatine Kinase MB.

& 6.60 \pm 0.68 h in group B. The ICU stay was 1.21 \pm 0.35 days in group A & 1.14 \pm 0.36 days in group B. The mean postoperative hospital stays were 3.70 \pm 0.72 days in group A & 3.83 \pm 0.98 days in group B. By matching group (A) with group (B), we found no statistically significant differences in terms of ventilation time, intensive care unit time, or overall hospital time.

One patient in group (A) experienced atrial fibrillation, and another in group (B) experienced a permanent stroke (B). The mortality rate in group (A) was 5% while in group (B) was 2.5%. When comparing complications in groups A & B, there was no statistically significant difference.

Discussion

Heart surgery requires cardioplegia to stop the heart and create a sterile operating environment free of blood. Traditional blood cardioplegia consists of potassium-rich solutions that induce cardiac arrest while cells stay in a depolarizer condition, preventing the propagation of myocardial electrical activity. Myocardial protection from the solution requires dosage every 20-30 minutes[10]. In this work, we aimed to compare between conventional crystalloid cardioplegia with modified del Nido cardioplegia in mitral valve regurgitation replacement surgery. According to our findings, no statistically significant difference was showed among the 2 groups according to potassium, glucose, creatinine and Cockcroft-Gault creatinine clearance (p > 0.05). Hemoglobin and hematocrit were significantly decrease in group A matched to group B (p < 0.001). No significant difference was showed among the 2 groups according to preoperative TIA or stroke (p > 0.05) as preoperative TIA or stroke was seen in 15% cases in group (A) & in five% in group (B). This came in line with[11].

Comparable with our findings, Haranal et al.[12], investigated One hundred patients who qualified were split into two groups: those who received del Nido cardioplegia and those who received BSTH cardioplegia solution. and stated that there was no significant difference as regard age, sex, BMI & cardiac complications (stroke).

Also, Floh et al.[13], observed that the primary cardiac diagnosis was insignificantly different between both studied groups.

Regarding our findings, no significant difference was found among group (A) & group (B) concerning ejection fraction measured preoperative and after 2 h (p > 0.05). Meanwhile there was significant rise of ejection fraction in group (B) matched to group (A) after 4 h (p = 0.017), after 6 h after 12 h ,after 18 h, & after 24 h. In each group, there was significant differences in ejection fraction between preoperative measurements and postoperative follow up measurements.

This came in line with Haranal et al.[12], who found preoperative EF was 66 + 8.1 in Del Nido group and was 66 + 9.2 in in BSTH with no significant difference between both groups however, Discharge 2D-echocardiography showed no significant difference in left ventricular ejection fraction (LVEF) among the del Nido group (65.6% + 8.9%) and the BSTH group (65.7% + 8.2%). Population diversity may account for this difference.

Our research presented that no significant difference was showed among the 2 groups according to postoperative inotropic support or number of inotropes (p > 0.05). This was in line with[11],[12].

In the present study, total PRBC Transfusion was significantly higher in group A matched to group B. This came in line with[12].

In the present research, there was significant rise of CK-MB in group (A) compared to group (B) after 1 h after 12 h and after 24 h (p < 0.001). In each group, there was significant steadily rise in CK-MB levels after 12 & 24 h compared to its level at first h. No significant difference was found among group (A) and group (B) regarding Troponin T measured after 1 h, and after 12 h (p > 0.05). Meanwhile there was significant rise of Troponin T in group (A) matched to group (B) after 24 h (p < 0,001). In each group, there was significant steadily increase in Troponin T levels after 12 & 24 h compared to its level at first h.

Troponin secretion As a diagnostic biomarker for myocardial survival, I is widely employed. Del Nido cardioplegia solution use was associated with decreased troponin levels in the juvenile population, according to a study by O'Brien and his associates[14].

In the study by Haranal et al.[12], Troponin T levels were somewhat greater in the BSTH cardioplegia group, However, there was no distinction among the groups in terms of the timing of troponin T release. Two solutions of del Nido and a blood-based Saint Thomas presented no difference in troponin levels when compared in a randomized controlled experiment[15].

Del Nido patients had lower rates of ventricular fibrillation after aortic cross-clamp removals, lower CK-MB values, lower glucose levels during CPB or less need for postoperative intravenous insulin, 34, lower need for trans operative inotropic support, and lesser troponin levels compared to patients treated with conventional blood cardioplegia[16].

In the same line with our finding, Kavala and Turkyilmaz's Kavala and Turkyilmaz[11], demonstrated that the DNC group's CK-MB levels at 1 & 24 h postoperatively were significantly lesser than those of the BC group (DNC = 5.82 ± 4.72 ng/mL and BC = $.27\pm 4.69$ ng/mL, respectively, P = 0.041; DNC = 13.30 ± 7.72 ng/mL and BC= 17.53 ± 7.26 ng/mL During one h, there was no difference in the troponin levels among the groups (DNC = 0.13 ± 0.05 ng/mL and BC = 0.24 ± 0.25 ng/mL, P = e0.099). Troponin levels in the DNC group were considerably lower after 24 h postoperatively (DNC = 0.28 ± 0.41 ng/mL and BC = 0.67 ± 1.03 ng/mL, P = e0.01).

In the present research, there was no discernible difference among group (A) and group (B) concerning lactate measurements taken after one hour and after twenty-four h (p > 0.05). After 12 h, there was a noticeable drop in lactate in group (A) matched to group (B). (p = 0.029). Each group's lactate levels significantly increased over the course of 12 and 24 h compared to their initial levels.

Unfortunately, the Plasma Lyte used as the basic solution for del Nido cardioplegia is not available in all countries, preventing its use in many cardiac facilities. An observational study by Kantathut et al.[18], compared the del Nido cardioplegia technique with the use of Ringer lactate as the base solution for myocardial preservation and clinical results (St. Thomas cardioplegia). The group that had the modified del Nido spent less time in the ICU and the hospital overall, need inotropic support less frequently, and experiencing fewer instances of postoperative fibrillation or flutter.

Our study showed that, no significant difference was found among group (A) & group (B) concerning ventilation duration, ICU stay & hospital stay (p > 0.05).

Additionally, a prior research found that there was no significant difference between ventilation duration, ICU stay & hospital stay (p > 0.05)[12].

In the present study, no significant difference was showed among group (A) & group (B) regarding complications (p > 0.05).

According to Kavala and Turkyilmaz, the DNC group experienced 17 obstacles whereas the BC group experienced 25 challenges[11]. None of the postoperative complications comparisons were statistically significant.

In the present research, there was no noticeable difference in in-hospital mortality among groups (A) & (B) (p > 0.05). This was consistent with Kavala and Turkyilmaz[11].

100 young patients having elective surgical correction of Fallot's tetralogy were randomly randomized to take either Custodiol or Del Nido cardioplegic solutions in Talwar et al.[19]. A shorter time spent on mechanical ventilation, a shorter stay in the hospital and intensive care unit, improved cardiac index preservation, increased cardiac output, lower inotropic scores, and reduced troponin-I release were all associated with the first. Myocardial edema was reduced and myofibrillar architecture and glycogen storage were better preserved using electronic microscopy in the del Nido group.

Conclusion

We report that Modified Del Nido Cardioplegia has better postoperative chemical parameters as CK-MB, Troponin T and Lactate in mitral valve surgery on adults. DNC is a safe alternative to conventional cardioplegia and has achieved at least the same results.

Limitations

Our study has some limitations. First off, since it was a onecenter study, other locations might have had different findings. Second, the sample size is really tiny. Moreover, Several outcomes, Lack of long-term follow-up makes it difficult to draw firm inferences about enhancements in outcomes like reduced cardiac marker levels and increased postpartum EF rates.

Abbreviations

DNCS: del Nido cardioplegia solution, EF: Ejection Fraction, SV: Stroke volume, SVV: Stroke volume variation, COP: Cardiac output, CI: Cardiac index, ASA: American Society of Anesthesiologists, CK-MB: Creatine Kinase MB, LVEF: left ventricular ejection fraction, ICU: Intensive care unite.

References

- Brancaccio G, Trezzi M, Chinali M, Vignaroli W, D'Anna C, Iodice F, et al. Predictors of survival in paediatric mitral valve replacement. Eur J Cardiothorac Surg. 2021 Jul;60(2):361–6. https://doi.org/10.1093/ejcts/ezab078 PMID:33582753
- Whittaker A, Aboughdir M, Mahbub S, Ahmed A, Harky A. Myocardial protection in cardiac surgery: how limited are the options? A comprehensive literature review. Perfusion. 2021 May;36(4):338–51. https://doi. org/10.1177/0267659120942656 PMID:32736492
- Cayir MC, Yuksel A. The use of del Nido cardioplegia for myocardial protection in isolated coronary artery bypass surgery. Heart Lung Circ. 2020 Feb;29(2):301–7. https://doi. org/10.1016/j.hlc.2018.12.006 PMID:30723044
- Eris C, Engin M, Erdolu B, Kagan As A. Comparison of del Nido Cardioplegia vs. blood cardioplegia in adult aortic surgery: is the single-dose cardioplegia technique really advantageous? Asian J Surg. 2022 May;45(5):1122–7. https:// doi.org/10.1016/j.asjsur.2021.09.032 PMID:34649799
- Zwolinski R, Jaszewski R, Jander S, Zagórski M, Adamek-Kosmider A, Bednarski I, et al. Single Dose of Del Nido Cardioplegic Solution in Comparison with St Thomas Hospital Solution in Mitral Valve Surgery: A Propensity Matched Comparison. Clinics in Surgery. 2019;•••:4.
- Balachandran V, Zhou X, Huang L, Tee R, Paul P, Dittmer J, et al. A Comparison of the Effects of Lidocaine or Procaine containing St. Thomas No. 2 Cardioplegia Solution on Post-operative Renal Function. Cardiol Cardiovasc Med. 2020;4(2):105–10. https://doi.org/10.26502/fccm.92920108.
- Luo H, Qi X, Shi H, Zhao H, Liu C, Chen H, et al. Single-dose del Nido cardioplegia used in adult minimally invasive valve surgery. J Thorac Dis. 2019 Jun;11(6):2373–82. https://doi. org/10.21037/jtd.2019.05.78 PMID:31372274

- Nakao M, Morita K, Shinohara G, Kunihara T. Modified Del Nido cardioplegia and its evaluation in a piglet model []. WB Saunders.]. Semin Thorac Cardiovasc Surg. 2021;33(1):84– 92. https://doi.org/10.1053/j.semtcvs.2020.03.002 PMID:32387781
- Mishra P, Jadhav RB, Mohapatra CK, Khandekar J, Raut C, Ammannaya GK, et al. Comparison of del Nido cardioplegia and St. Thomas Hospital solution - two types of cardioplegia in adult cardiac surgery. Kardiochir Torakochirurgia Pol. 2016 Dec;13(4):295–9. https://doi.org/10.5114/kitp.2016.64867 PMID:28096823
- Li Y, Lin H, Zhao Y, Li Z, Liu D, Wu X, et al. Del Nido cardioplegia for myocardial protection in adult cardiac surgery: a systematic review and meta-analysis. ASAIO J. 2018;64(3):360–7. https://doi.org/10.1097/ MAT.00000000000652 PMID:28863040
- Kavala AA, Turkyilmaz S. Comparison of del Nido cardioplegia with blood cardioplegia in coronary artery bypass grafting combined with mitral valve replacement. Rev Bras Cir Cardiovasc. 2018;33(5):496–504. https://doi. org/10.21470/1678-9741-2018-0152 PMID:30517259
- Haranal M, Chin HC, Sivalingam S, Raja N, Mohammad Shaffie MS, Namasiwayam TK, et al. Safety and effectiveness of Del Nido cardioplegia in comparison to blood-based St. Thomas cardioplegia in congenital heart surgeries: a prospective randomized controlled study. World J Pediatr Congenit Heart Surg. 2020 Nov;11(6):720–6. https://doi. org/10.1177/2150135120936119 PMID:33164692
- Floh AA, Das S, Haranal M, Laussen PC, Crawford-Lean L, Fan CS, et al. Comparison between Del Nido and conventional blood cardioplegia in pediatric open-heart surgery. Perfusion. 2023 Mar;38(2):337–45. https://doi. org/10.1177/02676591211054978 PMID:35143733
- O'Brien JD, Howlett SE, Burton HJ, O'Blenes SB, Litz DS, Friesen CL. Pediatric cardioplegia strategy results in enhanced calcium metabolism and lower serum troponin T. Ann Thorac Surg. 2009 May;87(5):1517–23. https://doi.org/10.1016/j. athoracsur.2009.02.067 PMID:19379896
- Gorjipour F, Dehaki MG, Totonchi Z, Hajimiresmaiel SJ, Azarfarin R, Pazoki-Toroudi H, et al. Inflammatory cytokine response and cardiac troponin I changes in cardiopulmonary bypass using two cardioplegia solutions; del Nido and modified St. Thomas': a randomized controlled trial. Perfusion. 2017 Jul;32(5):394–402. https://doi.org/10.1177/0267659117691119 PMID:28152655
- Vistarini N, Laliberté E, Beauchamp P, Bouhout I, Lamarche Y, Cartier R, et al. Del Nido cardioplegia in the setting of minimally invasive aortic valve surgery. Perfusion. 2017 Mar;32(2):112–7. https://doi.org/10.1177/0267659116662701 PMID:27469246
- Misra S, Srinivasan A, Jena SS, Bellapukonda S. Myocardial protection in adult cardiac surgery with del NIDO versus blood cardioplegia: a systematic review and meta-analysis. Heart Lung Circ. 2021 May;30(5):642–55. https://doi.org/10.1016/j. hlc.2020.10.016 PMID:33281072
- Kantathut N, Cherntanomwong P, Khajarern S, Leelayana P. Lactated Ringer's as a Base Solution for del Nido Cardioplegia. J Extra Corpor Technol. 2019 Sep;51(3):153–9. https://doi. org/10.1051/ject/201951153 PMID:31548737
- Talwar S, Chatterjee S, Sreenivas V, Makhija N, Kapoor PM, Choudhary SK, et al. Comparison of del Nido and histidinetryptophan-ketoglutarate cardioplegia solutions in pediatric patients undergoing open heart surgery: A prospective randomized clinical trial. J Thorac Cardiovasc Surg. 2019 Mar;157(3):1182–1192.e1. https://doi.org/10.1016/j. jtcvs.2018.09.140 PMID:33197997